128 related articles for article (PubMed ID: 36584099)
1. Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients.
Herman B; Bruni A; Zain E; Dzulhadj A; Oo AC;
PLoS One; 2022; 17(12):e0279184. PubMed ID: 36584099
[TBL] [Abstract][Full Text] [Related]
2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
3. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
4. Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study.
Herman B; Wong MC; Viwattanakulvanid P
PLoS One; 2022; 17(7):e0271385. PubMed ID: 35862378
[TBL] [Abstract][Full Text] [Related]
5. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
7. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients.
Fujii S; Ibe Y; Ishigo T; Inamura H; Kunimoto Y; Fujiya Y; Kuronuma K; Nakata H; Fukudo M; Takahashi S
J Infect Chemother; 2021 Jul; 27(7):1051-1057. PubMed ID: 33902990
[TBL] [Abstract][Full Text] [Related]
8. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
Çap M; Bilge Ö; Işık F; Burak C; Karagöz A; İnci Ü; Akyüz A; Aslan B; Altıntaş B; Altındağ R; Kaya İ; Adıyaman MŞ; Süleymanoğlu M; Kaya Ş; Baysal E
J Electrocardiol; 2020; 63():115-119. PubMed ID: 33181454
[TBL] [Abstract][Full Text] [Related]
9. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
Suzuki M; Imai T; Sakurai A; Komoto S; Ide T; Lim CK; Shintani A; Doi Y; Murata T
J Infect Chemother; 2021 Sep; 27(9):1350-1356. PubMed ID: 34176716
[TBL] [Abstract][Full Text] [Related]
10. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
11. Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study.
Alattar RA; Abdalla S; Abdallah T; Kazman R; Qadmour A; Ibrahim T; Alhariri B; Shaar SH; Bajwa A; Alimam A; Qazi R; Ben Abid F; Daghfal J; Eldeeb A; Shukri K; Elsayed A; Rustom F; Alsamawi M; Abdelmajid A; Basulto MAP; Cobian AAR; Abukhattab M; Alkhal A; Almaslamani MA; Omrani AS
J Infect Public Health; 2022 Oct; 15(10):1061-1064. PubMed ID: 36087547
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
[TBL] [Abstract][Full Text] [Related]
13. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna ; Kighoma PM; Koundouno FR; Réné Lolamou ; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D;
PLoS Med; 2016 Mar; 13(3):e1001967. PubMed ID: 26930627
[TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
[TBL] [Abstract][Full Text] [Related]
15. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
[TBL] [Abstract][Full Text] [Related]
16. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA
J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.
Mutair AA; Shamou J; Alhumaid S; Layqah L; Ahmed GY; Thoyaja K; Mohaini MA; Almahmoud S; Barry M; Khan A; Dhama K; Al-Jamea LH; Woodman A; Rabaan AA
J Infect Public Health; 2022 Apr; 15(4):389-394. PubMed ID: 35299062
[TBL] [Abstract][Full Text] [Related]
19. Sotrovimab Lowers the Risk of COVID-19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates.
Saheb Sharif-Askari F; Ali Hussain Alsayed H; Tleyjeh I; Saheb Sharif-Askari N; Al Sayed Hussain A; Saddik B; Hamid Q; Halwani R
Clin Pharmacol Ther; 2022 Dec; 112(6):1214-1223. PubMed ID: 35780295
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
